Theravance (THRX) Reports Better-Than-Expected Q1 Loss of $0.31
More News related to THRX
- Theravance to Present at the Deutsche Bank 2009 Biotech Boston Confab
- Theravance Announces New Employment Inducement Awards
- Theravance (THRX) MAA for Telavarion Validated by EMEA
- Theravance Announces That EMEA Has Completed the Validation Phase for the Telavancin MAA for the Treatment of Nosocomial Pneumonia and Complicated Skin and Soft Tissue Infections
- Theravance Receives Complete Response Letter on the Telavancin NDA for the Treatment of Nosocomial Pneumonia
More News related to Earnings
- Unilever (UL) Annouces Total Recall of Slim-Fast Cans
- Steris (STE) Sinks After FDA Notice on Concerns About the Steris System 1 Processor
- Watson Pharmaceuticals (WPI) Files New Drug Application with FDA for Generic Rozerem
- St. Jude (STJ) Receives U.S. FDA Approval for Penta Surgical Lead
- AstraZeneca (AZN) Gets U.S. FDA Approval for SEROQUEL XR Antidepressants
Theravance Inc. (Nasdaq: THRX) reports Q1 loss of $0.31, 1 cent better than the analyst estimate of ($0.32). Revenue for the quarter was $9.5 million, versus the consensus of $7.6 million.
Related Categories
EarningsStocks Mentioned
+0.20Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
